医薬品製造の世界市場 - 市場規模、シェア、成長分析：薬剤別、製造プロセス別（原薬製造、完成品製剤製造）、治療領域別 - 業界予測（2023年～2030年）

世界の医薬品製造の市場規模は2021年に4,259億米ドルとなりました。同市場は、予測期間中（2023年～2030年）に15.9%のCAGRで拡大し、2023年の5,721億米ドルから2030年には1兆6,071億6,000万米ドルに成長する見通しです。

世界の医薬品製造市場は、ヘルスケア領域における極めて重要なセクターとして繁栄を続けています。研究開発、医薬品製造の領域に位置するこの市場は、様々な要因の融合によって推進されています。世界人口の増加、慢性疾患の増加、医療技術の進化などです。新規医薬品、個別化医療、生物学的製剤への意欲は、市場拡大を推進する強力な原動力となっています。加えて、ヘルスケアインフラの普及、ヘルスケアアクセシビリティの向上を目指した政府の取り組み、医薬品製造施設に対する投資の増大も、総体的に市場の堅調な成長に寄与しています。とはいえ、市場の進展に課題がないわけではないことは注目に値します。厳しい規制、価格設定に関連する圧力、知的財産権に関連する複雑さなどが、市場全体の発展を阻害しかねない潜在的なハードルとして立ちはだかっています。

世界の医薬品製造市場の促進要因となるのは、ヘルスケア製品と医薬品ソリューションに対する世界規模での需要が高まっていることです。世界の人口の増加と慢性疾患や感染症の増加が相まって、医薬品に対する需要が顕著に増加しています。さらに、医療技術の進歩や高齢化も相乗的に、先駆的な医薬品や治療法の必要性を高めています。これに対応するため、製薬メーカーは生産能力を増強し、研究開発への投資を行い、新興国市場の需要拡大に効果的に対応するために斬新な製造技術を導入する必要に迫られています。

医薬品製造市場における顕著な阻害要因は、厳しい規制環境です。政府や規制機関は、医薬品の安全性、有効性、品質を保証するために厳しい基準やベンチマークを設けています。これらの基準を遵守するためには、インフラ、強固な品質管理の枠組み、綿密な文書化などに多額の投資を行う必要があります。これらの規制を逸脱した場合、厳しい罰則が課され、企業の評判が低下する可能性があります。さらに、複雑で時間のかかる新薬の承認プロセスは、製品の迅速なイントロダクションを妨げ、患者への重要な医薬品の供給を遅らせる可能性があります。このような複雑な規制上の課題は、潜在的な新規参入企業にとって障壁となり、医薬品製造の努力に内在する全体的な費用と時間の両方を増大させます。

当レポートは、世界の医薬品製造市場について調査し、市場の概要とともに、薬剤別、製造プロセス別、治療領域別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

親市場分析

市場規模

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題

主要な市場の洞察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 動向分析
• スタートアップ分析
• 原材料分析
• イノベーションマトリックス
• パイプライン製品分析
• マクロ経済指標
• トップ投資分析
• 主な成功要因
• 競合の程度

市場力学と見通し

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• 規制状況
• ポーター分析

世界の医薬品製造市場、薬剤別

• 市場概要
• 処方薬
• 市販薬
• 生物製剤

世界の医薬品製造市場、製造プロセス別

• 市場概要
• 医薬品原薬（API）製造
• 完成品製剤（FDF）製造
• 包装

世界の医薬品製造市場、治療分野別

• 市場概要
• 心血管
• 腫瘍
• 中枢神経系
• 呼吸器系
• 感染症

世界の医薬品製造市場、地域別

• 市場概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

競合情勢

• 主要企業プロファイル
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis International AG
  • Roche Holding AG
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Sanofi
  • AstraZeneca
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences, Inc
  • Takeda Pharmaceutical Company Limited
  • Novo Nordisk A/S
  • Amgen Inc.
  • Bayer AG
  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company, Limited
  • Teva Pharmaceutical Industries Ltd

Global Pharmaceutical Manufacturing Market size was valued at USD 425.9 billion in 2021 and is poised to grow from USD 572.10 billion in 2023 to USD 1607.16 billion by 2030, at a CAGR of 15.9% during the forecast period (2023-2030).

The global pharmaceutical manufacturing market continues to flourish as a pivotal sector within the healthcare realm. Anchored in the realms of research, development, and the production of medicinal substances, this market is propelled forward by an amalgamation of factors. These encompass the upward trajectory of global population figures, the escalating incidence of chronic ailments, and the stride of medical technology's evolution. The impetus for novel pharmaceuticals, individualized medicinal approaches, and biologics acts as a formidable driving force that propels the market's expansion. Additionally, the proliferation of healthcare infrastructure, governmental initiatives aimed at enhancing healthcare accessibility, and the augmented investment in pharmaceutical manufacturing facilities collectively contribute to the robust growth of the market. Nonetheless, it's noteworthy that the market's progress is not devoid of challenges. Stringent regulations, pressures linked to pricing considerations, and complexities associated with intellectual property rights loom as potential hurdles that could impede the overall advancement of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Manufacturing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The global pharmaceutical manufacturing industry can be segmented into various categories based on factors such as drug type, manufacturing process, therapeutic area, and geography. In terms of drug type, the industry encompasses the production of prescription drugs, over-the-counter medications, and biologics. The manufacturing process can be divided into active pharmaceutical ingredient (API) manufacturing, finished dosage form (FDF) manufacturing, and packaging. Therapeutic areas covered by the industry include cardiovascular, oncology, central nervous system, respiratory, and infectious diseases. Geographically, the global pharmaceutical manufacturing sector is spread across major regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Driver

A catalyst propelling the global pharmaceutical manufacturing market is the escalating requisition for healthcare products and medicinal solutions on a global scale. The mounting worldwide populace, coupled with an uptick in chronic maladies and infectious ailments, has instigated a marked upswing in the demand for pharmaceutical interventions. Furthermore, progressions in medical technology and the prevalence of an aging demographic have synergistically augmented the call for pioneering pharmaceuticals and therapies. In response, pharmaceutical manufacturers are compelled to amplify their production capacities, channel investments into research and development endeavors, and embrace novel manufacturing technologies to effectively cater to the expanding market requisites.

Restraint

A prominent hindrance within the pharmaceutical manufacturing market stems from the exacting regulatory milieu. Governments and regulatory bodies institute stringent norms and benchmarks to ensure the safety, effectiveness, and caliber of pharmaceutical offerings. Adhering to these standards necessitates substantial investments in infrastructure, robust quality control frameworks, and meticulous documentation. Deviation from these regulations can lead to severe penalties and detriment to a company's repute. Furthermore, the intricate and time-intensive regulatory endorsement process for new medicinal agents can impede the swiftness of product introductions, thus prolonging the availability of vital medications to patients. These intricate regulatory challenges erect barriers for potential new entrants, thereby elevating both the overall expenses and the time frame intrinsic to pharmaceutical manufacturing endeavors.

Market Trends

A notable trend within the global pharmaceutical manufacturing arena is the escalating demand for personalized medicine and targeted therapeutic interventions. The advancements in technology and genomics have ushered in an era of precision-oriented and individualized treatments, prompting a transformation in pharmaceutical manufacturing dynamics, marked by a transition to smaller production batches and adaptable manufacturing procedures. Moreover, the pursuit of biologics and biosimilars has gained traction, propelled by the surge in chronic ailments and the necessity for groundbreaking therapies. Simultaneously, a pronounced emphasis on sustainability and ecologically conscious practices has taken root, with pharmaceutical manufacturers directing their efforts towards waste reduction, bolstering energy efficiency, and embracing environmentally friendly production protocols, aligning with both regulatory stipulations and consumer anticipations.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune
• Research Methodology
• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Key Market Insights
• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition
• Market Dynamics & Outlook
• Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
  • Regulatory Landscape
  • Porters Analysis
• Competitive rivalry
• Threat of Substitute Products
• Bargaining Power of Buyers
• Threat of New Entrants
• Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
• Political Impact
• Economic Impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global Pharmaceutical Manufacturing Market by Drug
• Market Overview
• Prescription drugs
• over-the-counter medications
• and biologics
• Global Pharmaceutical Manufacturing Market by Manufacturing process
• Market Overview
• Active pharmaceutical ingredient (API) manufacturing
• finished dosage form (FDF) manufacturing
• and packaging
• Global Pharmaceutical Manufacturing Market by Therapeutic area
• Market Overview
• Cardiovascular
• oncology
• central nervous system
• respiratory
• and infectious diseases
• Global Pharmaceutical Manufacturing Market Size by Region
• Market Overview
• North America
• USA
• Canada
  • Europe
• Germany
• Spain
• France
• UK
• Rest of Europe
  • Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
  • Latin America
• Brazil
• Rest of Latin America
  • Middle East & Africa (MEA)
• GCC Countries
• South Africa
• Rest of MEA
• Competitive Landscape
• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
• By Development
• By Company
• By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021
• Key Company Profiles
• Johnson & Johnson (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Pfizer Inc. (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Novartis International AG (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Roche Holding AG (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Merck & Co., Inc. (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GlaxoSmithKline plc (United Kingdom)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Sanofi (France)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • AstraZeneca (United Kingdom)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • AbbVie Inc. (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Bristol-Myers Squibb Company (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Eli Lilly and Company (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Gilead Sciences, Inc. (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Novo Nordisk A/S (Denmark)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Amgen Inc. (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Bayer AG (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Astellas Pharma Inc. (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Boehringer Ingelheim GmbH (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Daiichi Sankyo Company, Limited (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Teva Pharmaceutical Industries Ltd. (Israel)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments